Core Viewpoint - Capital界金控 (00204) has received a winding-up petition from creditors due to unpaid loans totaling HKD 6.2 million, including interest, with a court hearing scheduled for October 22, 2025 [1] Group 1 - The company submitted a winding-up petition to the High Court of the Hong Kong Special Administrative Region on August 11, 2025 [1] - The petition is based on the unpaid principal amount of loans that were pre-paid by the petitioners [1] - The hearing for the petition is set for October 22, 2025 [1]

Group 1 - The company Capital界金控 (00204) has received a winding-up petition from creditors regarding its financial obligations [1] - The petition was submitted to the High Court of the Hong Kong Special Administrative Region on August 11, 2025, and is based on unpaid principal amount of HKD 6.2 million along with interest [1] - The hearing for the petition is scheduled for October 22, 2025, at the High Court of Hong Kong [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 內幕消息 清盤呈請 本公告由資本界金控集團有限公司（「本公司」）根據香港聯合交易所有限公司 證券上市規則（「上市規則」）第13.09(2)及13.25(1)(b)條以及香港法例第571章證券 及期貨條例第XIVA部的內幕消息條文（定義見上市規則）作出。 於二零二五年八月十三日，本公司接獲本公司債權人（「呈請人」）針對本公司 於二零二五年八月十一日向香港特別行政區高等法院（「香港高等法院」）提交 的清盤呈請（「呈請」），以根據香港法例第32章公司（清盤及雜項條文）條例（「公 司（清盤及雜項條文）條例」）的條文對本公司進行清盤。呈請乃有關根據呈請 人預先墊付的若干貸款的未償還本金額6,200,000港元連同利息。呈請將於二零 二五年十月二十二日在香港高等法院聆訊。 呈請的影響 資本界金控集團有限公司 CAPITAL REALM FINANCIAL HOLDINGS GROUP LIMITED （於開曼群島註冊 ...

Group 1 - The core viewpoint of the article is that Capital界金控 (00204) has signed a strategic cooperation letter of intent with Henan Life Tree Biotechnology Co., Ltd. (Life Tree) [1] - Life Tree is a biotechnology company focused on autonomous innovation, integrating cell research, clinical transformation, and industrial equipment to create a cutting-edge technology matrix [1] - The strategic cooperation is aligned with the long-term development goals and business strategies of the company, potentially providing profit growth opportunities for both parties [1]

Core Viewpoint - The announcement indicates that Capital World Financial Holdings (00204) has signed a strategic cooperation letter of intent with Henan Life Tree Biotechnology Co., Ltd, aiming to enhance long-term development goals and business strategies [1] Group 1: Company Overview - Life Tree is a biotechnology company driven by independent innovation, integrating cell research, clinical transformation, and industrial equipment [1] - The company focuses on self-developed automated equipment and medical devices, breaking technical barriers and leading the new standard for large-scale and standardized cell preparation [1] Group 2: Strategic Cooperation - The strategic cooperation is expected to create potential profit growth points for both parties, aligning with the overall interests of the company and its shareholders [1] - The collaboration aims to address diverse needs through customized cell application solutions, emphasizing the commitment to advancing biotechnological innovation [1]

Group 1 - The core point of the article is that Capital界金控 (00204.HK) has signed a strategic cooperation letter of intent with Henan Life Tree Biotechnology Co., Ltd. ("Life Tree") [1] - Life Tree is a biotechnology company focused on autonomous innovation, integrating cell research, clinical transformation, and industrial equipment capabilities [1] - The strategic cooperation is expected to align with the long-term development goals and business strategies of the company, potentially providing profit growth opportunities for both parties [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 戰略合作意向書 本公告乃由資本界金控集團有限公司（以下簡稱「本公司」，連同其附屬公司統稱為「本集 團」）按自願性基準作出，以將本集團業務發展之最新消息告知本公司股東及潛在投資者。 -1- 本公司董事（「董事」）會（「董事會」）欣然公告，本公司近期與河南生命樹生物工程有限 公司（「生命樹」）簽訂了戰略合作（「戰略合作」）意向書（「意向書」）。 生命樹是一家生物工程有限公司，以自主創新為驅動，融合細胞科研、臨床轉化與產業設備 之力，構建前沿科技矩陣。自研全自動化設備及醫療器械，破技術壁壘，領航細胞"規模化、 標準化製備"新航標。深耕細胞儲存、臨床研究與藥物研發，定制個性化細胞應用方案，精 準回應多元需求。立行業潮頭，踐科技使命，矢志推動生物科技革新，書寫生命健康華章。 本公司認為該等意向書項下擬進行的戰略合作符合本集團之長期發展目標及業務發展策略。 本次與生命樹的戰略合作可為雙方帶來潛在的利潤增長點 ...

Group 1 - The company received a total of 5 valid applications for the rights issue, amounting to 2.3764 million shares, which represents approximately 1.53% of the total shares offered under the rights issue [1] - As of the record date, there were no excluded shareholders, and the total number of unallocated rights issue shares subject to compensation arrangements was 153 million shares [1] - The company has appointed a placement agent to facilitate the subscription of unallocated rights issue shares, with the placement expected to commence on August 7, 2025, and conclude by August 13, 2025 [1] Group 2 - The company will not issue any unallocated rights issue shares that are not placed under the compensation arrangements, leading to a corresponding reduction in the scale of the rights issue [2]

资本界金控(00204)发布公告，于2025年8月4日(星期一)下午四时正(即最后接纳时限)，公司已接获合共5 份根据暂定配额通知书提呈的有效申请及接纳，涉及合共237.64万股供股股份，占供股项下提呈的供股 股份总数约1.53%。 预期配售代理将于2025年8月7日(星期四)开始配售未获认购供股股份，而有关配售将不迟于2025年8月 13日(星期三)下午四时正结束。 公司将不会发行任何未根据补偿安排配售的未获认购供股股份，而供股规模将相应调减。 于记录日期，概无除外股东。根据上述暂定配额通知书项下有效申请及接纳的结果，受补偿安排规限的 未获认购供股股份总数为1.53亿股供股股份，而除外股东未售供股股份的数目则为零股。公司已根据上 市规则第7.21(1)(b)条，透过与配售代理订立配售协议以作出补偿安排，据此，公司有条件委任配售代 理及配售代理有条件同意担任公司的配售代理，以根据配售协议的条款按竭诚基准促使承配人认购未获 认购供股股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供說明，並不構成收購、購買或認購本公司任何證券的邀請或要約。 資本界金控集團有限公司 CAPITAL REALM FINANCIAL HOLDINGS GROUP LIMITED （於開曼群島註冊成立並於百慕達續存之有限公司） （股份代號：204） 有效申請及接納供股股份的結果；及 補償安排下的未獲認購供股股份及除外股東未售供股股份數目 茲提述資本界金控集團有限公司（「本公司」）日期為二零二五年七月二十一日 的供股章程（「供股章程」），內容有關供股。除非另有界定，本公告所用詞彙與 供股章程所界定者具有相同涵義。 有效申請及接納供股股份的結果 董事會宣佈，於二零二五年八月四日（星期一）下午四時正（即最後接納時限）， 本公司已接獲合共5份根據暫定配額通知書提呈的有效申請及接納，涉及合共 2,376,392股供股股份，佔供股項下提呈的供股股份總數約1.53% 。 – 1 – 承董事會命 補償安排下的未獲 ...